Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Jul 24, 2018 11:00am
141 Views
Post# 28358779

RE:RE:The drop obviously is not due to quarterly rebalancing !

RE:RE:The drop obviously is not due to quarterly rebalancing !20 PE is likely low given the growth rate in earnings.

I added more under $10 yesterday and will continue to add if the market decides to push it down again (in the absence of news).

bfw


PoorOpinion wrote:
JayjayUSA12007 wrote:
Have someone checked short interest in Canada and US ?
If SI is stable, then seems to me whichever funds bought the convert must have sold their holdings. After all, the converts are just like call options. Their holding report would reveal this.
The ultimate goal is to shake out retails AND gaining profits in the process.
By taking out stop losses by selling at lower share price, someone is positioned to "harvest" shares. They won't stop suppressing until they would accumulate at least 50% of float.
Nothing you can do about it, unless you guys have enough fund to keep buying.


I don't quite understand what you are saying. You think an entity (or a few) are being allowed to play this stock any way they want? The market is made of presumably millions of entities, many with small pockets like us but many with large pockets. What's to stop any of these entities stepping in and doing their own harvesting, taking advantage of what others have sown. Isnt this how the market works, if a stock is percieved as cheap anybody (big or small pockets) can step in and make some money. Presumably it isnt happening. Personally I'd still consider Theratech a high risk/high reward stock and that comes with the volatility you might expect.. 

These numbers might be off - If you accept a P/E of 20 then a $10 SP needs around $40million profits to support it. As a recent article noted the confirmed 200 trogarzo patients represent $10mil annually for theratech, and roughly speaking Trogarzo revenue equals theratech profits. So the SP advances only on strong FUTURE business. So we still need to see trogarzo get established and grow to support higher SP. I totally agree with everybody that all the signals point to that happening, hopefully later this year it becomes apparent. Until then anybody can book profits, lets face it with hindsight the near $15 highs are looking very attractive atm for anybody with lingering doubts.


Bullboard Posts